Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From XOMA Corporation
Zydus and Lupin are gearing up for the US launch of a generic to Astellas Pharma’s blockbuster drug Myrbetriq (mirabegron) while Aurobindo expects a longer wait. Meanwhile, Torrent is preparing to defend its market share in chronic therapies in India as other companies increasingly target this segment
The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?
Outlook Therapeutics is hoping to secure EU marketing approval for the first ophthalmic formulation of bevacizumab.
The European Medicines Agency is due to decide whether to back pan-EU marketing authorization for 11 new products, including four orphan drugs.
- Large Molecule
- Other Names / Subsidiaries
- Enumeral Biomedical Inc.
- XOMA Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.